Cargando…

Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy

Diabetes mellitus (DM) affects >350 million people worldwide. With many complications that can reduce the patient’s quality of life, vision loss is one of the most debilitating disorders it can cause. Active research in the field of diabetes includes microvascular complications in diabetic retino...

Descripción completa

Detalles Bibliográficos
Autores principales: Popescu, Mihaela, Bogdan, Cătălina, Pintea, Adela, Rugină, Dumitriţa, Ionescu, Corina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037275/
https://www.ncbi.nlm.nih.gov/pubmed/30013318
http://dx.doi.org/10.2147/DDDT.S156941
_version_ 1783338305509654528
author Popescu, Mihaela
Bogdan, Cătălina
Pintea, Adela
Rugină, Dumitriţa
Ionescu, Corina
author_facet Popescu, Mihaela
Bogdan, Cătălina
Pintea, Adela
Rugină, Dumitriţa
Ionescu, Corina
author_sort Popescu, Mihaela
collection PubMed
description Diabetes mellitus (DM) affects >350 million people worldwide. With many complications that can reduce the patient’s quality of life, vision loss is one of the most debilitating disorders it can cause. Active research in the field of diabetes includes microvascular complications in diabetic retinopathy (DR). Disturbances in the balance of pro-angiogenesis and anti-angiogenesis factors can lead to the progression of DR. The retinal pigment epithelium (RPE) is the outermost layer of the retina, and it is essential in maintaining the visual function. The RPE produces and secretes growth factors as well as protective agents which maintain structural integrity of the retina. Small natural molecules, such as resveratrol, may influence neurotrophic factors of the retina. The pigment epithelium-derived factor (PEDF) and thrombospondin-1 (TSP-1) are secreted by RPE cells. These two proteins inhibit angiogenesis and inflammation in RPE cells. An alteration of their production contributes to various eye diseases. There is a critical balance between two important factors secreted on opposite sides of the RPE: at the basal side, vascular endothelial growth factor (VEGF; acts on the choroidal endothelium) and, on the apical side, PEDF (acts on neurons and photoreceptors). Resveratrol inhibits VEGF expression in human adult RPE cells and limits the development of proliferative vitreoretinopathy, by attenuating transforming growth factor-β2-induced wound closure and cell migration. Possible new mechanisms could include PEDF and TSP-1 expression alterations under physiological and pathological conditions. Resveratrol is currently of interest due to its capacity to influence the cell’s secretory activity. Some limitations arise from its low bioavailability. Several drug delivery systems are currently tested, promising to improve tissue concentrations. This article reviews biological pathways involved in the pathogenesis of DR that could be influenced by resveratrol. A study of these pathways could identify new potential targets for the reduction of diabetic complications.
format Online
Article
Text
id pubmed-6037275
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-60372752018-07-16 Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy Popescu, Mihaela Bogdan, Cătălina Pintea, Adela Rugină, Dumitriţa Ionescu, Corina Drug Des Devel Ther Review Diabetes mellitus (DM) affects >350 million people worldwide. With many complications that can reduce the patient’s quality of life, vision loss is one of the most debilitating disorders it can cause. Active research in the field of diabetes includes microvascular complications in diabetic retinopathy (DR). Disturbances in the balance of pro-angiogenesis and anti-angiogenesis factors can lead to the progression of DR. The retinal pigment epithelium (RPE) is the outermost layer of the retina, and it is essential in maintaining the visual function. The RPE produces and secretes growth factors as well as protective agents which maintain structural integrity of the retina. Small natural molecules, such as resveratrol, may influence neurotrophic factors of the retina. The pigment epithelium-derived factor (PEDF) and thrombospondin-1 (TSP-1) are secreted by RPE cells. These two proteins inhibit angiogenesis and inflammation in RPE cells. An alteration of their production contributes to various eye diseases. There is a critical balance between two important factors secreted on opposite sides of the RPE: at the basal side, vascular endothelial growth factor (VEGF; acts on the choroidal endothelium) and, on the apical side, PEDF (acts on neurons and photoreceptors). Resveratrol inhibits VEGF expression in human adult RPE cells and limits the development of proliferative vitreoretinopathy, by attenuating transforming growth factor-β2-induced wound closure and cell migration. Possible new mechanisms could include PEDF and TSP-1 expression alterations under physiological and pathological conditions. Resveratrol is currently of interest due to its capacity to influence the cell’s secretory activity. Some limitations arise from its low bioavailability. Several drug delivery systems are currently tested, promising to improve tissue concentrations. This article reviews biological pathways involved in the pathogenesis of DR that could be influenced by resveratrol. A study of these pathways could identify new potential targets for the reduction of diabetic complications. Dove Medical Press 2018-07-03 /pmc/articles/PMC6037275/ /pubmed/30013318 http://dx.doi.org/10.2147/DDDT.S156941 Text en © 2018 Popescu et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Popescu, Mihaela
Bogdan, Cătălina
Pintea, Adela
Rugină, Dumitriţa
Ionescu, Corina
Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title_full Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title_fullStr Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title_full_unstemmed Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title_short Antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
title_sort antiangiogenic cytokines as potential new therapeutic targets for resveratrol in diabetic retinopathy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6037275/
https://www.ncbi.nlm.nih.gov/pubmed/30013318
http://dx.doi.org/10.2147/DDDT.S156941
work_keys_str_mv AT popescumihaela antiangiogeniccytokinesaspotentialnewtherapeutictargetsforresveratrolindiabeticretinopathy
AT bogdancatalina antiangiogeniccytokinesaspotentialnewtherapeutictargetsforresveratrolindiabeticretinopathy
AT pinteaadela antiangiogeniccytokinesaspotentialnewtherapeutictargetsforresveratrolindiabeticretinopathy
AT ruginadumitrita antiangiogeniccytokinesaspotentialnewtherapeutictargetsforresveratrolindiabeticretinopathy
AT ionescucorina antiangiogeniccytokinesaspotentialnewtherapeutictargetsforresveratrolindiabeticretinopathy